AQTIS Revenue and Competitors
Estimated Revenue & Valuation
- AQTIS's estimated annual revenue is currently $238.2M per year.
- AQTIS's estimated revenue per employee is $403,750
Employee Data
- AQTIS has 590 Employees.
AQTIS's People
Name | Title | Email/Phone |
---|
AQTIS Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $43.9M | 136 | 8% | N/A | N/A |
#2 | $238.2M | 590 | N/A | N/A | N/A |
#3 | $35.2M | 109 | 6% | N/A | N/A |
#4 | $404.7M | 895 | N/A | N/A | N/A |
#5 | $173.6M | 430 | 5% | N/A | N/A |
#6 | $42.3M | 131 | 5% | N/A | N/A |
#7 | $77.5M | 218 | 17% | N/A | N/A |
#8 | $25.5M | 79 | 1% | N/A | N/A |
#9 | $3.7M | 19 | -21% | N/A | N/A |
#10 | $145.8M | 361 | 6% | N/A | N/A |
What Is AQTIS?
Contexte général\r\nL'AQTIS, l'Alliance québécoise des techniciens de l'image et du son représente plus de 3,000 artistes concepteurs, artisans et techniciens du Québec dans plus d'une centaine de métiers de l'industrie de l'image et du son. Afin de compléter son équipe de relations de travail, l’AQTIS est à la recherche d’une personne créative et professionnelle pour combler un poste permanent de conseiller en relations de travail.
keywords:N/AN/A
Total Funding
590
Number of Employees
$238.2M
Revenue (est)
N/A
Employee Growth %
N/A
Valuation
N/A
Accelerator
AQTIS News
MONTRÉAL, le 22 avril 2022 /CNW Telbec/ - L'Association québécoise des techniciens et techniciennes de l'image et du son (AQTIS),...
... Cutera, Cynosure, Merz Pharma, Galderma, Lumenis, Syneron Medical, Valeant Pharmaceuticals, Alma Lasers, AQTIS Medical.
... Leading Players Allergan, Cutera, Cynosure, Merz Pharma, Galderma, Lumenis, Syneron Medical, Bausch Health, Alma Lasers, AQTIS Medical.
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $184.7M | 591 | -12% | N/A |
#2 | $204.5M | 606 | 56% | N/A |
#3 | $204.9M | 607 | 11% | N/A |
#4 | $75M | 625 | N/A | N/A |
#5 | $75M | 626 | 2% | N/A |